Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3-Reference-Cited by-同舟云学术

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

Published:2014-04 Issue:1 Volume:7 Page:86-93
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Sun Chong,Hobor Sebastijan,Bertotti Andrea,Zecchin Davide,Huang Sidong,Galimi Francesco,Cottino Francesca,Prahallad Anirudh,Grernrum Wipawadee,Tzani Anna,Schlicker Andreas,Wessels Lodewyk F.A.,Smit Egbert F.,Thunnissen Erik,Halonen Pasi,Lieftink Cor,Beijersbergen Roderick L.,Di Nicolantonio Federica,Bardelli Alberto,Trusolino Livio,Bernards Rene

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference29 articles.

1. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3;Abel;J. Clin. Invest.,2013

2. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers;Adjei;J. Clin. Oncol.,2008

3. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity;Barretina;Nature,2012

4. A missing link in genotype-directed cancer therapy;Bernards;Cell,2012

5. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms;Bonni;Science,1999

Cited by 271 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells;Frontiers in Cell and Developmental Biology;2024-06-14

2. Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers;Journal of Clinical Investigation;2024-06-06

3. Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer;British Journal of Cancer;2024-05-31

4. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs;Cancer Drug Resistance;2024-04-29

5. Combinatorial strategies to target RAS-driven cancers;Nature Reviews Cancer;2024-04-16